Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples